Covx is a biotechnology company. It engages in the discovery and development of long-acting biological therapies called CovX-Bodies. Its products pipeline focuses on targets that inhibit tumor angiogenesis and modulate metabolic disorders. Their products pipeline includes CVX-045, a thrombospondin-1 mimetic CovX-Body; TSP-1, a negative regulator of angiogenesis that acts as a therapeutic target in oncology; CVX-060, a selective angiopoietin-2 antagonist COVX-BODY; and CVX-096, a long-acting GLP-1 mimetic COVX-BODY. Covx was founded by Carlos Barbas in 2002 and is headquartered in San Diego, California.
